A-Synaptic has successfully completed an in vitro Franz Cell study showing the capability of its GT4 transdermal technology to move CBD through the dermal membrane in clinically meaningful quantities. Please contact the company for details.
In addition, A-Synaptic has successfully completed an in vivo human bioavailability study conducted in Canada as authorized by Health Canada. This study has been published in a peer reviewed scientific journal. The study showed the GT4 speed and efficiency in moving clinically meaningful amounts of both CBD and THC through the skin and into systemic circulation.